Form 4: DexCom EVP Jereme M. Sylvain Reports Stock Grant and Holdings

Executive Vice President and CFO of DexCom, Jereme M. Sylvain, reports the acquisition of 26,053 shares of common stock through a restricted stock unit grant.

Summary

• Jereme M. Sylvain, EVP and CFO of DexCom Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 8, 2024, Sylvain acquired 26,053 shares of DexCom common stock through a grant of restricted stock units (RSUs).
• These RSUs vest in three equal annual installments from the grant date.
• The reported transaction leaves Sylvain with a total of 97,195 shares of DexCom common stock, including unvested RSUs from previous grants.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices and aligns executive interests with shareholders.

Positives

• The grant of restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Executive compensation through stock grants is a common practice in the technology and healthcare industries to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in publicly traded companies, particularly in high-growth sectors like medical technology.
• Companies like Medtronic, Abbott, and Boston Scientific also utilize stock options and restricted stock units as part of their executive compensation plans.
• The vesting schedules are generally in line with industry standards, promoting long-term commitment.

Stakeholder Impact

• The stock grant incentivizes the CFO to focus on long-term value creation, benefiting shareholders.
• The grant does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates